Sitagliptin in clinical practice: A new approach in the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 10, 2008, Pages 1705-1720

  Florentin, M ^a   Liberopoulos, E N ^a   Mikhailidis, D P ^b   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adverse effects; Diabetes; Dipeptidyl peptidase 4 inhibitors; Hypoglycemia; Sitagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIGUANIDE DERIVATIVE; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; MICROSOMAL AMINOPEPTIDASE INHIBITOR; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VILDAGLIPTIN; WARFARIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARCINOGENICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC DIET; DIARRHEA; DIET RESTRICTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EXERCISE; FLATULENCE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY FAILURE; LACTATION; LIFESTYLE MODIFICATION; LIVER FAILURE; MEDLINE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PAIN; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; PREGNANCY; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN EXFOLIATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ADULT; AGED; BLOOD PRESSURE; CHILD; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; PREGNANCY; PYRAZINES; TRIAZOLES;

EID: 48049124324     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.10.1705     Document Type: Review

References (118)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
2. American Diabetes Association. All about diabetes. Available from: http://www.diabetes.org/about-diabetes.jsp [Last assessed 10 May 2008]
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
5. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
6. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
7. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006;29(Suppl 1):S4-2
8. Nathan DM. Finding new treatments for diabetes - how many, how fast... how good? N Engl J Med 2007;356:437-40
9. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173-5
10. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40
11. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4
12. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84:3434-8
13. Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 1989;38:902-5
14. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-25
15. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541-4
16. Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81-6
17. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003;144:5145-8
18. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004;47:4135-41
19. Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004;145:2653-59
20. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967;46:1954-62
21. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52
22. Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357-66
23. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7
24. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31
25. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874-9
26. Flamez D, Van Breusegem A, Scrocchi LA, et al. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes 1998;47:646-52
27. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999;96:14843-7
28. Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004;53:1326-35
29. FDA approves once-daily JANUVIA(TM), the first and only DPP-4 inhibitor available in the United States for type 2 diabetes. Available from: www.genengnews.com [Last assessed 10 May 2008]
30. Januvia, inn: sitagliptin. Available from: www.emea.europa.eu [Last assessed 10 May 2008]
31. Januvia, sitagliptin tablets [product information]. Whitehouse Station, NJ: Merck&Co., Inc.; 2006
32. Drug price inquiry. Available from: www.drugstore.com/pharmacy [Last assessed 10 May 2008]
33. Glucophage price-from approved pharmacy. Available from: www.stephanspencer.com [Last assessed 10 May 2008]
34. Exermet P 515; (generic actoplus met, pioglitazone + metformin). Available from: www.freedom-pharmacy.com [Last assessed 10 May 2008]
35. Compare metformin prices on PharmacyChecker.com. Available from: www.pharmacychecker.com [Last assessed 10 May 2008]
36. Aschner P, Kipnes M, Lunceford J, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
37. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
38. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
39. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
40. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329-39
41. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-8
42. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80
43. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing merformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
44. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-93
45. Goldstein BJ, Feingtos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87
46. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45
47. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68
48. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008;48:592-8
49. Jackson EK, Dubinion JH, Mi Z. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol 2008;35:29-34
50. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206
51. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-8
52. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8
53. Pi-Sunyer FX, Schweizer A. Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8
54. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23
55. Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85
56. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007;24:955-61
57. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55
58. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23
59. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
60. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008;57:190-8
61. Januvia (Sitagliptin Phosphate) drug description. Available from: www.rxlist.com/cgi/generic/januvia.htm [Last assessed 10 May 2008]
62. Sitagliptin phosphate drug for diabetes by Merck. Available from: www.sitagliptin.org.uk [Last assessed 10 May 2008]
63. Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc) 2007;43:681-9
64. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94
65. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24
66. Mentlein R. Cell-surface peptidases. Int Rev Cytol 2004;235:165-213
67. Gorrell MD & Yu DMT. Diverse functions in a conserved structure: the dipeptidyl peptidase IV gene family. In: Robinson, JW. editors, Trends in protein research. Nova Science Publishers, Inc., New York, 2005. p. 1-78
68. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005;108:277-92
69. Langner J & Ansorge S 2002; Ectopeptidases: CD13/aminopeptidase N and CD26/dipeptidylpeptidase IV in medicine and biology. Kluwer/Plenum, New York
70. Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999;29:1768-78
71. Matsumoto Y, Bishop GA, McCaughan GW. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology 1992;15:1048-53
72. Abbott CA, Yu DM, Woollatt E, et al. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000;267:6140-50
73. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 2004;1679:18-28
74. Yu DM, Wang XM, McCaughan GW, Gorrell MD. Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J 2006;273:2447-60
75. Wrenger S, Faust J, Friedrich D, et al. Attractin, a dipeptidyl peptidase IV/CD26-like enzyme, is expressed on human peripheral blood monocytes and potentially influences monocyte function. J Leukoc Biol 2006;80:621-9
76. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 2004;109:855-66
77. Emanuele E, Minoretti P, Martinelli V, et al. Circulating levels of soluble CD26 are associated with phobic anxiety in women. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1334-6
78. Reinhold D, Biton A, Pieper S, et al. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int Immunopharmacol 2006;6:1935-42
79. Bank U, Heimburg A, Helmuth M, et al. Triggering endogenous immunosuppressive mechanisms by combined targeting of dipeptidyl peptidase IV (DPIV/CD26) and aminopeptidase N (APN/CD13): a novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol 2006;6:1925-34
80. Thielitz A, Ansorge S, Bank U, et al. The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases. Front Biosci 2008;13:2364-75
81. Stremenova J, Krepela E, Mates V, et al. Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int J Oncol 2007;31:785-92
82. Jones B, Adam S, Miller GT, et al. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 2003;102:1641-8
83. Gaicu R, Fenouillet E, Devaux C, et al. CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behav Brain Res 2006;166:230-5
84. Grouzmann E, Monod M, Landis B, et al. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J 2002;16:1132-4
85. Christopherson KW 2nd, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 2002;169:7000-8
86. Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004;305:1000-3
87. Christopherson KW 2nd, Uralil SE, Porecha NK, et al. G-CSF- and GM-CSF-induced upregulation of CD26 peptidase downregulates the functional chemotactic response of CD34+CD38- human cord blood hematopoietic cells. Exp Hematol 2006;34:1060-8
88. Tian C, Bagley J, Forman D, Iacomini J. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther 2006;13:652-8
89. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94
90. Burkey BF, Hoffmann PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;[Epub ahead of print]
91. Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 2005;8:51-8
92. Mistry GC, Bergman AT, Luo WL, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007;47:159-64
93. Krishna R, Bergman A, Larson P, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 2007;47:165-74
94. Pregnancy and the Drug Dilemma. Available from: www.fda.gov [Last assessed 10 May 2008]
95. Merck & Co, Inc. Januvia (sitagliptin phosphate) tablets 25 qd, 50 qd and 100 mg qd. ODE Decisional Review Memorandum [US Food and Drug Administration Center for Drug Evaluation and Research Website]. Available from: http://www.fda.gov/cder/foi/nda/2006/ 021995s000_MedR.pdf. [Last assessed 10 May 2008]
96. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 2008;117:574-84
97. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
98. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
99. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
100. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
101. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93
102. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211-28
103. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
104. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94
105. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(Suppl 1):S68-71
106. Goke B. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002;1:329-36
107. Parholer KG, Otto C, Geiss HC, et al. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 - results of a pilot study. Exp Clin Endocrinol Diabetes 2005;113:49-52
108. Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-7
109. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-7
110. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
111. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-108
112. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-9
113. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702
114. Raskin P, Rendeff M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32
115. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-57
116. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-73
117. Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7:53-72
118. Mikhailidis DP, Press M. The importance treating multiple cardiometabolic risk factors in patients with type 2 diabetes. Expert Opin Pharmacother 2007;8:3009-20